课题基金 / 基金详情

Endothelial Myocyte Matrix in Cardiac Remodeling

Endothelial Myocyte Matrix in Cardiac Remodeling
心脏重塑中的内皮肌细胞基质
批准号:
7614563
负责人:
Suresh C. Tyagi
金额:
$37.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-05 至 2014-08-31
关键词:
AbbreviationsAcetylcholineAcidsAntigensAntioxidantsAortaApoptosisArteriesArteriovenous fistulaBasement membraneBradykininCD31 AntigensCardiacCellsChronicClinicalCoinCollagenCongestive Heart FailureCouplingCpG Island Methylator PhenotypeCystathionineCytoskeletonDiastoleDiastolic blood pressureDiastolic heart failureDilated CardiomyopathyDisulfidesEchocardiographyElastinEndothelial CellsEndotheliumEventExtracellular MatrixFibrosisFistulaFunctional disorderFundingGasesGelatinase AGelatinase BGenerationsGoalsHeartHeart failureHistologyHydrogen SulfideHydroxyeicosatetraenoic AcidsHypertrophyIn SituLaboratoriesLeftLeft ventricular structureLyaseMatrix MetalloproteinasesMeasuresMediatingMitochondriaMusMuscleMuscle CellsMyocardialNADHNADPH OxidaseNG-Nitroarginine Methyl EsterNicotinamide adenine dinucleotideNitric OxideNitric Oxide SynthaseNitroprussideNuclearOperative Surgical ProceduresOxidation-ReductionOxidative StressPAR-1 ReceptorPoly(ADP-ribose) PolymerasesPreparationPrincipal InvestigatorProcessProstaglandinsProtein Kinase CProteomeRadiolabeledReactive Nitrogen SpeciesReactive Oxygen SpeciesRelaxationRoleSecondary toSodiumSourceStressSulfhydryl CompoundsSystemSystoleTechniquesTestingTimeTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-3Tissue Inhibitor of MetalloproteinasesVentricularWestern Blottingarginine methyl esterdrinking waterhuman AKAP13 proteinhuman NOS3 proteinin vivoinnovationnovelpreventprogesterone 11-hemisuccinate-(2-iodohistamine)programspublic health relevanceradiotracerrelaxing factorresearch studyresponsesham surgerytissue inhibitor of metalloproteinase 4

项目摘要

项目成果

Suresh C. Tyagi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall goal of this project is to understand the mechanism of endocardial endothelial-myocyte (E-M) dysfunction in chronic heart failure. Studies from the previous funding period suggested that endocardial endothelial dysfunction is associated with increased oxidized-matrix accumulation (fibrosis), activation of latent resident myocardial matrix metalloproteinases (MMPs) and inactivation of cardiac tissue inhibitor of metalloproteinase (TIMP-4) secondary to oxidative and proteolytic stresses. Administration of TIMP-4 ameliorated both the formation of reactive oxygen species (ROS, oxidative stress) and MMP activation (proteolytic stress). In addition, we discovered the induction of proteinase activated receptor-1 (PAR-1). However, the role of PAR-1 in fibrosis and E-M uncoupling remains poorly defined. H2S gas is the most potent antioxidant in mitigating oxidative stress and recent studies have implicated a cardioprotective role of H2S. The central hypothesis of this competitive renewal proposal is that during chronic heart failure the oxidative and proteolytic stresses induce PAR-1, leading to generate mitochondrial (mt) ROS and reactive nitrogen species (RNS) and mitochondrial nitric oxide synthase (mtNOS), respectively, thus activating the latent resident cardiac MMPs. These events disrupt the MMP/TIMP axis, causing fibrosis between endothelium and myocyte. Treatment with H2S alleviates fibrosis and mitigates E-M uncoupling. Therefore, the specific aims of this proposal are: #1: To determine whether chronic left ventricle (LV) volume overload causes mitochondrial oxidative stress (ROS and RNS) by inducing NADPH oxidase (p47 subunit), mtNOS and PAR-1, and H2S alleviates mitochondrial oxidative stress. #2: To determine whether chronic LV volume overload causes cardiac fibrosis by increasing collagen/elastin ratio, MMP-2, -9, -13, TIMP-1, -3, decreasing TIMP-4, and inducing PAR-1, and H2S mitigates cardiac fibrosis. #3: To determine whether chronic LV volume overload causes E-M dysfunction and LVH by inducing PAR-1 and H2S decreases E-M uncoupling. Chronic heart failure will be created by LV volume overload by aorta-venacava fistula (AVF) in wild type (WT), PAR-1-/+, iNOS-/-, MMP-9-/-, TIMP-3-/-, and TIMP-4++/++ mice, treated with or without NaHS, a H2S donor. PUBLIC HEALTH RELEVANCE: The myocyte contraction and relaxation are synchronized only when myocytes are connected by extracellular matrix (ECM). We coined the term endothelial-myocyte (E-M) coupling because endocardial endothelial (EE) cells derived cardio-active agents modulate myocyte contraction in systole and relaxation in diastole. The endothelium in the heart is the least studied system, because unlike conduit arteries, the endocardial endothelium is buried in the muscle and it is difficult to separate its role in myocyte function. We developed a new technique, "cardiac rings," in which endothelium dependent or independent cardiac contraction and relaxation can be examined separately in LV and RV. There are two novel aspects of this proposal: 1) the proposed experiments will demonstrate the role of PAR-1 in the underlying mechanism of fibrosis and endothelial-myocyte uncoupling in heart failure; and 2) will have clinical translational ramifications of H2S in treating diastolic heart failure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Remote Hind Limb Ischemia Mechanism of Cardioprotection
  • 批准号:
    10247852
  • 项目类别:
  • 资助金额:
    $6.49万
  • 财政年份:
    2020
  • 负责人:
    Suresh C. Tyagi
  • 依托单位:
Reversing Skeletal Muscle Myopathy by Hydrogen Sulfide
  • 批准号:
    10557832
  • 项目类别:
  • 资助金额:
    $33.88万
  • 财政年份:
    2018
  • 负责人:
    Suresh C. Tyagi
  • 依托单位:
Remote Hind Limb Ischemia Mechanism of Cardioprotection
  • 批准号:
    10215605
  • 项目类别:
  • 资助金额:
    $38.5万
  • 财政年份:
    2018
  • 负责人:
    Suresh C. Tyagi
  • 依托单位:
Remote Hind Limb Ischemia Mechanism of Cardioprotection
  • 批准号:
    10438112
  • 项目类别:
  • 资助金额:
    $10.45万
  • 财政年份:
    2018
  • 负责人:
    Suresh C. Tyagi
  • 依托单位:
海外基金